AMAndré J. McDonald

André J. McDonald

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


André J. McDonald has a total of 87 co-authors. Here are the top co-authors by number of shared publications:

  • Christine M. Wickens

    Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Canada

    9 shared publications
  • Robert E. Mann

    Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

    7 shared publications
  • Tara Elton-Marshall

    Institute for Mental Health Policy Research, Centre for Addiction and Mental Health

    7 shared publications
  • Amanda Doggett

    Peter Boris Centre for Addictions Research St. Joseph's Healthcare Hamilton Hamilton Canada

    5 shared publications
  • Hayley A. Hamilton

    Institute for Mental Health Policy Research, Centre for Addiction and Mental Health

    5 shared publications
  • James MacKillop

    Peter Boris Centre for Addictions Research, St Joseph’s Healthcare Hamilton and McMaster University, Hamilton, Ontario, Canada

    5 shared publications

Latest Publications

  • Open Access

    Population-level associations of interpersonal trauma during childhood and adulthood with mental health and addiction problems

    by André J. McDonald, Nigel E. Turner, Anca R. Ialomiteanu, John McCready, Dov Millstone, Hayley A. Hamilton, Tara Elton-Marshall, Jürgen Rehm, Paul Kurdyak, Gabriela Ilie, et al.

    Interpersonal trauma during childhood and adulthood is associated with many adverse mental health and addiction outcomes. However, methodological issues of previous studies make it difficult to estimate and compare these associations at the population level. The objective of this study was to estimate and compare associations of self-reported interpersonal trauma during childhood and adulthood with several adverse mental health and addiction-related outcomes using population-based data. Using general population survey data among adults aged 18 + years (n = 4,016), we conducted logistic regression analyses to estimate the association between interpersonal trauma (never, childhood only, adulthood only, childhood and adulthood) and seven outcomes including psychological distress, suicidal ideation, ADHD symptoms, hazardous drinking, daily cannabis use, problematic electronic device use, and problem gambling. We also estimated population attributable fractions for any lifetime trauma in the seven outcomes. Overall, 18.3% of adults reported interpersonal trauma (9.2% childhood only, 5.0% adulthood only, and 4.1% both childhood and adulthood). In our main models, interpersonal trauma was significantly associated with psychological distress, suicidal ideation, ADHD symptoms, hazardous drinking, daily cannabis use, and problematic electronic device use, but not problem gambling. There was no evidence of interaction between childhood trauma and adulthood trauma for any of the outcomes either on the multiplicative or additive scale. Population attributable fraction estimates of lifetime trauma were significant for all seven outcomes ranging from 5.5% to 12.4%. Interpersonal trauma during either childhood or adulthood is strongly associated with, and may account for a significant proportion of, mental health and addiction problems at the population level. Based on current evidence, policymakers should place a higher priority on developing prevention strategies for interpersonal trauma to reduce the burden of mental health and addiction problems.

  • Open Access

    Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

    by Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi

    Background and aims: Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics of individuals with ED visits involving hallucinogens. Design: Repeated cross‐sectional study using health administrative data. Setting: Ontario, Canada. Participants: All individuals aged 10 years and older living in Ontario, Canada, from 2008 to 2023 (population of 13 492 974 in 2023). Measurements: Annual rates of ED visits involving hallucinogens overall and by demographic and clinical subgroups. Linear regression was used to calculate the average annual percent change (AAPC) in rates of visits. Findings: We identified 7735 individuals with an ED visit involving hallucinogens [median (interquartile range) age at the time of visit, 24 (19–33) years; 71.5% male] who incurred 8274 visits. Visits displayed high acuity, with 54% arriving by ambulance and 13.2% requiring hospitalization. In 42% of visits another substance or co‐morbid mental health diagnosis was noted as contributing to the visit. Annual rates of ED visits involving hallucinogens increased by 97.9% between 2008 and 2023 (3.3 to 6.5 visits per 100 000 individuals) with visits increasing on average by 5.6% per year [AAPC = 5.6%; 95% confidence interval (CI) = 3.9%, 7.3%]. Relative increases between 2008 and 2023 were higher in those aged 25–44 (relative change (RC) 192.5%: AAPC = 8.5%; 95% CI = 6.0, 11.0] compared with other ages (age 45 + RC 125%: AAPC = 5.5%; 95% CI = 3.6, 7.3; age 19–24 RC 75.0%: AAPC = 5.3%; 95% CI = 3.4, 7.3). Visits increased more in individuals with anxiety disorders (RC 247%: AAPC = 7.5%; 95% CI = 5.2%, 9.9%) or prior diagnosis of schizophrenia (RC 401%: AAPC = 12.2; 95% CI = 8.2%, 16.4%) than those without any mental health disorder (RC 85.5%: AAPC = 4.9%; 95% CI = 3.1, 6.7). Comparable changes over time were observed in males (RC 101.1%: AAPC = 4.7; 95% CI = 2.9, 6.5) and females (RC 85.9%: AAPC = 6.0%; 95% CI = 4.2, 7.8) and for those in the richest (RC 124.0%: AAPC = 5.7%; 95% CI = 4.6%, 6.9%) or poorest neighbourhoods (RC 70.2%: AAPC = 5.2%; 95% CI = 3.7%, 6.7%). Conclusions: The 97.9% increase in emergency department visits involving hallucinogens in Ontario, Canada, from 2008 to 2023 may reflect rising hallucinogen use and the need for ongoing monitoring, particularly in adults aged 25–44 years and those with co‐morbid mental health diagnoses.

  • Open Access

    Changes in Cross-Sectional Associations Between Cannabis Use and Anxiety, Depression, and Suicidality in a Nationally Representative Sample of Canadians From 2012 to 2022: Évolution des relations transversales entre la consommation de cannabis et la dépression, l’anxiété et les idées suicidaires au sein d’un échantillon représentatif de Canadiens à l’échelle nationale, de 2012 à 2022

    by Jillian Halladay, Chris Ji, Katholiki Georgiades, André McDonald, Matthew Sunderland, Tim Slade, Cath Chapman, James MacKillop

    Objective: As epidemiological patterns of cannabis use and internalizing problems evolve globally, it is critical to reassess their associations—particularly in the post-legalization and post-pandemic context . Methods: Participants were assessed in the 2012 Canadian Community Health Survey's Mental Health Component (CCHS-MH; n = 25,113) and 2022 Mental Health and Access to Care Survey (MHACS; n = 9,861), two nationally representative cross-sectional epidemiologic surveys of Canadians aged 15+. Robust Poisson Regression analyses examined associations between frequency of cannabis use and past 12-month generalized anxiety disorder (GAD), major depressive episode (MDE), and suicidality assessed using the World Health Organization Composite International Diagnostic Interview. Results: Between 2012 and 2022, the prevalence of GAD, MDE, and cannabis use (any and 2+/week) approximately doubled, while suicidality remained unchanged in the full sample but increased by 44% among youth. Across all models, cannabis frequency was consistently associated with a higher prevalence of GAD, MDE, and suicidality in a frequency-dependent fashion. Additive interactions between year and cannabis on each of the outcomes demonstrated stronger associations in 2022 versus 2012. For example, from 2012 to 2022, those using cannabis 2+/week (relative to no use) had a: (1) prevalence ratio (PR) for GAD of 2.3 (95% CI, 1.6–3.4) increase to 4.5 (3.8–5.2); (2) PR for MDE of 3.0 (2.3–3.9) increase to 5.2 (4.6–5.7); and (3) PR for suicidality of 3.0 (2.1–4.0) increase to 5.4 (4.7–6.1). Select moderation effects indicated associations between cannabis and MDE or suicidality strengthened more among youth (15–24 vs. 25+), and associations with GAD strengthened more among females. Conclusions: Cannabis use was consistently related to a higher prevalence of internalizing problems, and these associations strengthened between 2012 and 2022. Given continued escalations in co-occurring cannabis use and internalizing problems, greater investment in early identification, intervention, and access to integrated substance use and mental health treatment is needed.


  • Open Access

    Adolescent cannabis use and psychological distress from 2013 to 2023: A population‐based study in Ontario, Canada

    by André J. McDonald, Amanda Doggett, Susan J. Bondy, Ian Colman, Steven Cook, Hayley A. Hamilton, Paul Kurdyak, Scott T. Leatherdale, Daniel T. Myran, Jürgen Rehm, et al.

    Background and aims: Epidemiologic research suggests that adolescent cannabis use is associated with psychological distress (i.e. depression and anxiety symptoms); however, most studies have relied on 20th‐century data, when cannabis was significantly less potent than today. This study aimed to estimate the association between adolescent cannabis use and psychological distress using contemporary population‐based data and examine the roles of time [as a proxy for increasing Δ9‐tetrahydrocannabinol (THC) potency], sex and age of initiation. Design: Representative cross‐sectional survey conducted biennially from 2013 to 2023. Setting: Ontario, Canada. Participants: 35 007 adolescents in grades 7 to 12. Measurements: Past‐year cannabis use was categorized as Never, 1–2 times, 3–9 times, 10–39 times or 40+ times. Psychological distress was measured with the Kessler‐6 scale using a cut‐off score of 13+ indicating anxiety/depression symptoms. Multivariable modified Poisson and least‐squares models were used to estimate the association between past‐year cannabis use and psychological distress. Survey year and sex were tested as effect modifiers on the multiplicative and additive scales. The association between school grade of cannabis use initiation and psychological distress was also estimated. Findings: From 2013 to 2023, the prevalence of psychological distress increased from 10.7% to 27.4%, whereas cannabis use decreased from 23.1% to 17.6%. Survey year and sex were statistically significant effect modifiers for the association between cannabis use and psychological distress with associations consistent with a super‐additive effect but not multiplicative synergy (additive interactions: P < 0.05; multiplicative interactions: P > 0.05). The association between cannabis use and psychological distress strengthened over time, particularly for those using 40+ times compared with abstinence (from 0% [95% confidence interval (CI) = −6% to 6%] adjusted prevalence difference in 2013 to 18% (95% CI = 11%–25%] adjusted prevalence difference in 2023). Independent of time, there was evidence of dose–response among females, but not males. A 5% (95% CI = 1%–10%) lower prevalence of psychological distress was observed per later school grade of cannabis use initiation. Conclusions: Psychological distress increased markedly among adolescents in Ontario, Canada, from 2013 to 2023. In that setting, adolescent cannabis use was statistically significantly associated with psychological distress, especially among females, and this association increased in magnitude over time, especially for those using most frequently. It is possible that adolescents are increasingly self‐medicating psychological distress with cannabis and/or that rising cannabis potency is increasingly contributing to psychological distress. While causality cannot be established, based on the precautionary principle, policymakers should prioritize cannabis prevention strategies that aim to reduce frequency of use, limit potency and delay age of initiation, particularly among females.


  • Open Access

    Examining bidirectional associations between cannabis use and internalizing symptoms among high-risk emerging adults: A prospective cohort study

    by Jillian Halladay, Kyla Belisario, André McDonald, Samuel Acuff, Amanda Doggett, Molly Garber, Andrea Maxwell, James Murphy, James MacKillop

    Background: The co-occurrence of cannabis use and internalizing symptoms, such as depression and anxiety, during emerging adulthood (18–25 years) is well documented. However, while bidirectional relationships are often assumed, empirical evidence is mixed. This study investigates bidirectional longitudinal relationships between cannabis frequency and consequences and internalizing symptoms (depressive and anxiety) among high-risk emerging adults. Methods: Data came from seven assessments collected over a 2-year period among 961 (54% female) high-risk emerging adults participating in two longitudinal cohorts (Ontario, Canada; Tennessee, USA). Assessments were at 4-month intervals spanning 2018–2020. Latent curve models with structured residuals were used to explore bidirectional between- and within-person relationships between cannabis-related variables and internalizing symptoms. Results: At baseline, higher levels of cannabis frequency and consequences were associated with higher internalizing symptoms. In between-person model components, cannabis-related and internalizing variables decreased across emerging adulthood. Significant within-person bidirectional relationships were observed, partially supporting both symptom-driven and substance-induced pathways, but the findings were specific to negative cannabis consequences, not frequency, and for depressive symptoms, not anxiety symptoms, for symptom-driven pathways. These bidirectional relationships were more pronounced among females and those surpassing clinical thresholds for internalizing symptoms at baseline. Conclusions: This study found evidence of bidirectional relationships between cannabis consequences and internalizing symptoms across emerging adulthood, with the prevailing direction from cannabis-related negative consequences to increases in internalizing symptoms. These findings highlight the importance of cannabis intervention in emerging adults, both to reduce consequences and to prevent internalizing disorders, especially targeting females and those with clinically elevated internalizing symptoms.


  • Open Access

    Changes in cannabis attitudes and perceptions in the five years following recreational legalization in Canada: Findings from an observational cohort study of community adults

    by Amanda Doggett, Kyla L. Belisario, André J. McDonald, Jane De Jesus, Emily Vandehei, Jessica Gillard, Laura Lee, James MacKillop


  • Open Access

    Association of recreational cannabis legalization with changes in medical, illegal, and total cannabis expenditures in Canada

    by André J. McDonald, Alysha Cooper, Amanda Doggett, Jillian Halladay, Kyla Belisario, James MacKillop


  • Open Access

    Cannabis Use and Misuse Following Recreational Cannabis Legalization

    by André J. McDonald, Amanda Doggett, Kyla Belisario, Jessica Gillard, Jane De Jesus, Emily Vandehei, Laura Lee, Jillian Halladay, James MacKillop

    Importance: An increasing number of jurisdictions have legalized recreational cannabis for adults, but most evaluations have used repeated cross-sectional designs, preventing examination of within-person and subgroup trajectories across legalization.Objective: To examine changes in cannabis use and misuse in the 5 years following legalization in Canada both overall and by prelegalization cannabis use frequency using a longitudinal design.Design, Setting, and Participants: This prospective cohort study included data from community-dwelling adults who participated in up to 11 biannual assessments from September 2018 to October 2023 in Ontario, Canada. Data were analyzed from November 2023 to January 2024.Exposure: Five years of recreational cannabis legalization (baseline wave was immediately prior to legalization).Main Outcome and Measures: Primary outcomes were cannabis use frequency and cannabis misuse, assessed using Cannabis Use Disorder Identification Test – Revised (CUDIT-R) score. Prelegalization cannabis use frequency, age, and sex were examined as moderators. Secondary outcomes included changes in cannabis product preferences over time.Results: The final cohort included 1428 community-dwelling adults aged 18 to 65 years (859 [60.2%] female; mean [SD] age, 34.5 [13.9] years). Mean retention was 90% across all waves. Linear mixed-effects modeling found a significant increase in cannabis use frequency, such that the mean proportion of days using cannabis increased by 0.35% (95% CI, 0.19% to 0.51%) per year (P < .001) in the overall sample (1.75% over 5 years). In contrast, CUDIT-R scores (on scale of 0 to 32) decreased significantly overall (β = −0.08 [95% CI, −0.10 to −0.06] per year; −0.4 over 5 years; P < .001), most notably with the onset of the COVID-19 pandemic. Interaction analyses indicated that prelegalization cannabis use frequency significantly moderated changes for both outcomes (P < .001). Specifically, cannabis use and misuse decreased among prelegalization frequent consumers and modestly increased among occasional users and nonusers. Cannabis product preferences shifted away from dried flower, hashish, concentrates, oil, tinctures, and topicals to edibles, liquids, and vape pens.Conclusions and Relevance: In this prospective cohort study of community-dwelling adults in Canada, cannabis use frequency increased modestly in the 5 years following legalization, while cannabis misuse decreased modestly. These changes were substantially moderated by prelegalization cannabis use, with more frequent consumers of cannabis before legalization exhibiting the largest decreases in both outcomes. Although longer-term surveillance is required, these results suggest Canadian recreational cannabis legalization was associated with modest negative and positive consequences among adults.


  • Open Access

    Examining bidirectional associations between cannabis use and internalizing symptoms among high-risk emerging adults: A prospective cohort study

    by Jillian Halladay, Kyla Belisario, André McDonald, Samuel Acuff, Amanda Doggett, Molly Scarfe, Andrea Maxwell, James Murphy, James MacKillop

    Purpose: The co-occurrence of cannabis use and internalizing problems, such as depression and anxiety, during emerging adulthood (18-25 years) is well documented, but the directionality is unclear. This study investigates the bidirectional longitudinal relationships between cannabis use (frequency and consequences) and internalizing problems (depressive and anxiety symptoms) among high-risk emerging adults. Methods: Data came from 7 assessment waves collected over a 2-year period among 900 (56% female) high-risk emerging adults participating in two longitudinal cohorts (Ontario, Canada; Tennessee, USA). Latent curve models with structured residuals were used to explore bidirectional between- and within-person relationships between cannabis-related variables and internalizing problems. Results: At baseline, higher cannabis use frequency and consequences were both associated with higher internalizing symptoms. In between-person models, both cannabis-related factors (frequency and consequences) and internalizing symptoms (depressive and anxiety symptoms) decreased across emerging adulthood. In within-person models, bidirectional relationships were observed (partially supporting both symptom-driven and substance-induced pathways), but cannabis consequences, rather than frequency, were most consistently related to subsequently higher internalizing problems (particularly depressive symptoms). These bidirectional relationships were more pronounced among females and those surpassing clinical thresholds for internalizing problems at baseline. Conclusions: This study found evidence of bidirectional relationships between cannabis involvement and internalizing problems across emerging adulthood, although the prevailing direction was from negative cannabis consequences to increases in internalizing. These findings highlight the importance of cannabis intervention in emerging adults, both to reduce consequences and prevent internalizing symptoms, especially targeting females and those with clinically elevated internalizing problems.

  • Open Access

    Legal Recreational Cannabis Sales and Opioid-Related Mortality in the 5 Years Following Cannabis Legalization in Canada: A Granger Causality Analysis

    by André J. McDonald, Alysha Cooper, Amanda Doggett, Kyla Belisario, James MacKillop

    Objective: Little is known about the population-level impact of recreational cannabis legalization on trends in opioid-related mortality. Increased access to cannabis due to legalization has been hypothesized to reduce opioid-related deaths because of the potential opioid-sparing effects of cannabis. The objective of this study was to examine the relations between national retail sales of recreational (non-medical) cannabis and opioid overdose deaths in the 5 years following legalization in Canada. Method: Using time-series data, we applied Granger causality methods to evaluate the association between trends in legal recreational cannabis sales and opioid-related deaths over time. Both sales and opioid deaths grew over time, with the latter exhibiting significant increases following the onset of the COVID-19 pandemic. Results: We found no support for the hypothesis that increasing post-legalization sales Granger caused changes in opioid-related deaths in British Columbia, Ontario, or at the national level. Conclusions: These findings suggest that increases in legal recreational cannabis sales following legalization were not meaningfully associated with changes in opioid-related mortality. Further examination with longer follow-up periods will be needed as the legal cannabis market becomes more entrenched in Canada, but these findings converge with previous work suggesting legalization is not related to opioid overdose mortality and further undermine that hypothesized link as a basis for legalization in other jurisdictions.